Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Lenz on Optimal Sequencing Strategies in CRC

September 10th 2020

Heinz-Josef Lenz, MD, FACP, discusses optimal sequencing strategies for the treatment of patients with colorectal cancer.

Dr. Morris on the Design of the COBRA Trial in Stage II Colon Cancer

September 8th 2020

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Dr. Halfdanarson on Investigational Agents in Driver-Negative CRC

September 3rd 2020

Thorvardur (Thor) Halfdanarson, MD, discusses investigational agents that are being evaluated in patients with colorectal cancer who do not harbor genomic alterations.

Dr. Grothey on Left- Versus Right-Sided Tumors in CRC

September 2nd 2020

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Later-Line Treatment Approaches Make Headway in CRC Management

September 2nd 2020

Axel Grothey, MD, explains the impact of tumor sidedness on treatment decisions and highlights novel later-line approaches that are under examination in colorectal cancer.

Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC

September 1st 2020

Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.

First Targeted Regimen Arrives for BRAF V600E-Mutant mCRC

September 1st 2020

The approval of encorafenib in combination with cetuximab advances the metastatic colorectal cancer paradigm, introducing a biomarker-specific regimen for patients with pretreated BRAF V600E–mutant disease.

Dr. Grothey on Biomarkers to Inform Metastatic CRC Treatment Decisions

August 31st 2020

Axel Grothey, MD, discusses biomarkers that can help to guide the treatment of metastatic colorectal cancer.

Dr. Meyerhardt on the Rationale for the CALGB/SWOG 80702 Trial in Colon Cancer

August 27th 2020

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.

Dr. Morris on the Role of Circulating Tumor DNA in Resected Colon Cancer

August 27th 2020

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

Dr. Chu on the Impact of the KEYNOTE-177 Trial in mCRC

August 21st 2020

Edward Chu, MD, MMS, discusses the impact of the phase 3 MK-3475-177/KEYNOTE-177 trial in metastatic colorectal cancer.

Novel Combinations Dominate Later-Line Metastatic CRC Treatment Landscape

August 20th 2020

Thorvardur (Thor) Halfdanarson, MD, discusses novel approaches under investigation in the later-line treatment of patients with CRC.

Road Map to Reducing Colorectal Cancer Deaths

August 20th 2020

Newer, cheaper and more personalized tests means more people tested and more lives saved.

Dr. Halfdanarson on Molecular Differences Between Left- Versus Right-Sided Tumors in CRC

August 12th 2020

Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.

Blood-Based Assay Could Soon Surface in Colorectal Cancer

August 4th 2020

Shai Friedland, MD, discusses the novel multimodal FirstSight test, which showed promise in identifying colorectal cancer, as well as precancerous polyps and advanced adenomas.

KEYNOTE-177 Cements Pembrolizumab as New Standard of Care in MSI-H/dMMR mCRC

August 4th 2020

Thierry Andre, MD, discusses the results of the KEYNOTE-177 trial in metastatic colorectal cancer.

Adding Celecoxib to FOLFOX Does Not Demonstrate DFS Benefit in Colon Cancer

August 4th 2020

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the addition of celecoxib to standard chemotherapy, stating that it did not significantly improve disease-free survival or overall survival in patients with colon cancer.

Lenz Lends Insight on Therapeutic Approaches Shaking Up Third-Line CRC Treatment

August 3rd 2020

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment approaches that are generating excitement in colorectal cancer.

Dr. Lenz on Later-Line Combo Approaches in CRC

July 28th 2020

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment combination approaches in colorectal cancer.

Dr. Ahn on Limitations of Targeted Therapy in CRC

July 24th 2020

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.